0000000000172031

AUTHOR

Annette Queisser-wahrendorf

showing 5 related works from this author

Glatiramer acetate during early pregnancy: A prospective cohort study

2016

Background: Only limited data are available on whether glatiramer acetate exposure during pregnancy has an effect on perinatal outcome. Objective: To determine the effect of glatiramer acetate exposure during pregnancy on pregnancy outcomes in women with multiple sclerosis. Methods: We compared the outcome of pregnancies of women with multiple sclerosis exposed to glatiramer acetate with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, lab…

Pregnancymedicine.medical_specialtyObstetricsbusiness.industryMultiple sclerosisBirth weightmedicine.disease03 medical and health sciences0302 clinical medicineNeurologyPremature birthConcomitantmedicine030212 general & internal medicineNeurology (clinical)Glatiramer acetatePregnancy outcomesProspective cohort studybusiness030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosi…

2015

Background: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients. Methods: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was…

AdultPediatricsmedicine.medical_specialtyMultiple SclerosisBirth weightGerman03 medical and health sciences0302 clinical medicinePregnancyGermanymedicineBirth WeightHumansImmunologic Factors030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyPregnancy registryPregnancyInterferon betabusiness.industryMultiple sclerosisInfant NewbornAbnormalities Drug-InducedInterferon-betamedicine.diseaselanguage.human_languageBody HeightAbortion SpontaneousPregnancy ComplicationsFirst trimesterPregnancy Trimester FirstNeurologylanguagePremature BirthFemaleNeurology (clinical)business030217 neurology & neurosurgeryMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Safety of potential breast milk exposure to IFN-β or glatiramer acetate

2019

ObjectiveTo determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.MethodsWe identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record.ResultsThe median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves dur…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosis41BreastfeedingBreast milkArticleChild DevelopmentPregnancyInterquartile rangemedicineHumansImmunologic FactorsRegistriesGlatiramer acetatePregnancyMilk Humanbusiness.industryPostpartum PeriodInfantGlatiramer AcetateInterferon-betamedicine.disease54Pregnancy ComplicationsBreast FeedingNeurologyFemaleMedian bodyNeurology (clinical)businessBreast feedingPostpartum periodmedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

Evidence for a teratogenic risk in the offspring of health personnel exposed to ionizing radiation?!

2016

Background The evidence concerning safety of occupational exposure to ionizing radiation on teratogenic effects mainly relies on animal models, disaster epidemiology and experience in cancer etiology. Following an explorative result on maternal exposure in medical occupations we conducted a feasibility study, addressing congenital anomalies (CA) in the offspring of health workers potentially exposed to radiation. Methods In a prospective follow-up study, we enrolled women, identified by mandatory registration at the office of radiation protection as wearing a dosimeter. The participating women answered a questionnaire and if pregnant agreed to an examination of their infant. CA were diagnos…

Embryologymedicine.medical_specialtyPregnancyObstetricsbusiness.industryOffspringGeneral Medicinemedicine.disease030210 environmental & occupational health030218 nuclear medicine & medical imagingIonizing radiation03 medical and health sciences0302 clinical medicineEnvironmental healthPediatrics Perinatology and Child HealthEpidemiologyCohortmedicineTeratogenic riskOccupational exposureRadiation protectionbusinessDevelopmental BiologyBirth Defects Research Part A: Clinical and Molecular Teratology
researchProduct

Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data

2017

ObjectiveTo validate the estimates of Global Burden of Disease (GBD) due to congenital anomaly for Europe by comparing infant mortality data collected by EUROCAT registries with the WHO Mortality Database, and by assessing the significance of stillbirths and terminations of pregnancy for fetal anomaly (TOPFA) in the interpretation of infant mortality statistics.Design, setting and outcome measuresEUROCAT is a network of congenital anomaly registries collecting data on live births, fetal deaths from 20 weeks’ gestation and TOPFA. Data from 29 registries in 19 countries were analysed for 2005–2009, and infant mortality (deaths of live births at age <1 year) compared with the WHO Mortality …

0301 basic medicineMalePediatrics030105 genetics & heredityInfant DeathGlobal Burden of Disease0302 clinical medicineCongenital anomaly ; DALY ; Global Burden of Disease ; YLL ; mortality.PregnancyPrenatal DiagnosisYLLEpidemiologyInfant MortalityPrevalenceMedicineEPIDEMIOLOGY030212 general & internal medicineRegistries1506DOWN-SYNDROMEPOPULATIONeducation.field_of_studyDALYAnomaly (natural sciences)Pregnancy OutcomeObstetrics and GynecologyGestational ageGeneral MedicineStillbirthUPDATED SYSTEMATIC ANALYSISPREVALENCEEuropeFetal Mortality/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleOriginal ArticleCHILD-MORTALITYAdultCOUNTRIESmedicine.medical_specialtyPopulationGestational AgeCongenital Abnormalities03 medical and health sciencesSDG 3 - Good Health and Well-beingJournal ArticleHumansCongenital anomalyAbortion Induced/statistics & numerical data; Adult; Congenital Abnormalities/diagnosis; Congenital Abnormalities/epidemiology; Europe/epidemiology; Female; Fetal Death/prevention & control; Fetal Mortality; Gestational Age; Global Burden of Disease/methods; Global Burden of Disease/statistics & numerical data; Humans; Infant; Infant Death/prevention & control; Infant Mortality; Infant Newborn; Male; Pregnancy; Pregnancy Outcome/epidemiology; Prenatal Diagnosis/methods; Prenatal Diagnosis/statistics & numerical data; Prevalence; Registries/statistics & numerical data; Stillbirth/epidemiology; Congenital anomaly; DALY; Global Burden of Disease; YLL; mortalityeducationFetal DeathPregnancybusiness.industryInfant NewbornInfantAbortion InducedNATIONAL CAUSESmedicine.diseasemortalityTRENDSInfant mortalityChild mortalityYears of potential life lostPediatrics Perinatology and Child HealthbusinessPRIMARY PREVENTIONDemography
researchProduct